Make an Inquiry

    Sorry, We are 100% Exporting company, We are not selling in India.

    Sodium Chloride 0.33% And Dextrose 5% Injection


    Product/Composition:-

    Sodium Chloride 0.33% And Dextrose 5% Injection

    Strength:-

    250ml / 500ml / 1000ml

    Form:-

    Injection

    Production Capacity

    1 Million Injection/Month

    Dextrose and Sodium Chloride Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration. These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.Dextrose and Sodium Chloride Injection, USP (dextrose and sodium chloride inj) is a sterile.

    Dextrose and Sodium Chloride Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration. These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.Dextrose and Sodium Chloride Injection, USP (dextrose and sodium chloride inj) is a sterile.

    The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.

    Dextrose and Sodium Chloride Injection, USP is indicated as a source of water, electrolytes, and calories.Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

    Read more...

    Tages :